Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for ...

Neurizon Therapeutics (ASX: NUZ) has announced encouraging outcomes from an independent study assessing its neuroprotective ...

Neurizon Therapeutics Ltd (ASX:NUZ) has yielded positive results from an independent study – conducted in collaboration with ...

NUZ-001 has shown it promotes healthy and viable brain tissues, potentially demonstrating its use to treat Alzheimer’s and ...

Mach 7 and Universal Biosensors have announced their CEOs will depart, while changes at the top are likely at other biotechs.

Neurizon Therapeutics' (ASX:NUZ) lead drug candidate has demonstrated positive results in the latest round of testing with ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Stockhead’s Tylah Tully chats with Neurizon Therapeutics (ASX:NUZ) managing director Michael Thurn about the company's goal ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the ...

In this episode, Tylah Tully gives the skinny on Neurizon Therapeutics (ASX:NUZ) HEALEY ALS Platform Trial, as the company ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...